2015
Comparative effectiveness of torsemide versus furosemide in heart failure patients: insights from the PROTECT trial
Mentz RJ, Velazquez EJ, Metra M, McKendry C, Chiswell K, Fiuzat M, Givertz MM, Voors AA, Teerlink JR, O'Connor CM. Comparative effectiveness of torsemide versus furosemide in heart failure patients: insights from the PROTECT trial. Future Cardiology 2015, 11: 585-595. PMID: 26403536, PMCID: PMC5558519, DOI: 10.2217/fca.15.56.Peer-Reviewed Original ResearchConceptsPROTECT trialComparative effectivenessHigher blood urea nitrogenEffects of torsemideProspective randomized trialsHeart failure patientsBlood urea nitrogenGreater disease severityDays postdischargeFailure patientsHeart failureLoop diureticsRandomized trialsRenal hospitalizationUrea nitrogenDisease severityPatientsFurosemideInverse probabilityTorsemideTrialsDeathOutcomesHospitalizationDiuretics
2008
Prognostic Implications of Left Ventricular Mass and Geometry Following Myocardial Infarction The VALIANT (VALsartan In Acute myocardial iNfarcTion) Echocardiographic Study
Verma A, Meris A, Skali H, Ghali JK, Arnold JM, Bourgoun M, Velazquez EJ, McMurray JJ, Kober L, Pfeffer MA, Califf RM, Solomon SD. Prognostic Implications of Left Ventricular Mass and Geometry Following Myocardial Infarction The VALIANT (VALsartan In Acute myocardial iNfarcTion) Echocardiographic Study. JACC Cardiovascular Imaging 2008, 1: 582-591. PMID: 19356485, DOI: 10.1016/j.jcmg.2008.05.012.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngiotensin II Type 1 Receptor BlockersCardiovascular DiseasesEuropeFemaleHeart VentriclesHumansHypertrophy, Left VentricularKaplan-Meier EstimateMaleMiddle AgedMyocardial InfarctionPredictive Value of TestsProportional Hazards ModelsRecurrenceRisk AssessmentRisk FactorsTetrazolesTime FactorsTreatment OutcomeUltrasonographyUnited StatesValineValsartanVentricular RemodelingConceptsLeft ventricular mass indexRelative wall thicknessHigh-risk myocardial infarctionAdverse cardiovascular eventsLeft ventricular massMyocardial infarctionLV geometryCardiovascular eventsConcentric remodelingEchocardiographic studyLV hypertrophyConcentric hypertrophyEccentric hypertrophyPrognostic implicationsVentricular massBaseline left ventricular mass indexMean left ventricular mass indexBaseline left ventricular massHigher relative wall thicknessBaseline LV massNonfatal cardiovascular outcomesAbnormal LV geometryComposite end pointVentricular mass indexConcentric LV hypertrophy